Business Wire

Secure Access is Broken. Fyde Enterprise Fixes It.

4.11.2019 14:00:00 EET | Business Wire | Press release

Share

Fyde, the new standard for Zero Trust, today announced Fyde Enterprise, a continuous, adaptive secure access solution that mitigates risk while protecting privacy and increasing performance. As digital transformation and the cloud transform the way we work and access apps, the disappearance of the traditional corporate perimeter creates new security risks and compliance challenges that break traditional solutions like VPNs. A powerful alternative to VPNs, Fyde Enterprise works on any infrastructure, any device, and with any application on a corporate network. Distributed businesses can now modernize remote access, enforce global security and access policies, and achieve seamless connectivity without compromising productivity.

Fyde, a first-time participant at Web Summit, is a featured startup and will be speaking on Centre Stage at the Breakout startups on November 4 at 5:00 pm and November 6 at 9:15 am. Fyde is also an exhibitor in the Beta Startup Programme on Tuesday, November 5.

Zero Trust for the Modern Enterprise

The Zero Trust paradigm assumes that all access is conditional and the network is always untrusted. Every interaction with the corporate network or cloud infrastructure must be granted contextual and conditional access based on continuous evaluation of device attributes (such as critical updates, security configuration and geographic location) and user identity (such as enforcing MFA or re-authentication) to ensure the highest levels of security.

Security teams must adapt to new requirements for the cloud, employee mobile devices, and evolving access dynamics associated with contractors, partners and remote employees. Fyde’s Zero Trust approach to secure access is driven by identity-aware access control and device-trust based security policies. Fyde enables secure, reliable and fast access to authorized apps and workloads on corporate networks and cloud infrastructure from any device, network, and location. Fyde also protects user identities from account takeover attacks.

“CISOs are frustrated by the failure of their traditional secure access solutions to deliver essential visibility and control over access to corporate resources, as well as to block emerging threats,” said Sinan Eren, Fyde CEO. “Fyde is built to address the security challenges created by the evolving threat landscape, while protecting employee privacy, boosting productivity, and ensuring compliance.”

Fyde Enterprise: The Onramp to Zero Trust

Fyde Enterprise is easy to deploy, monitor and manage. Security and IAM teams can sync with their user directory for seamless onboarding and deprovisioning of users and devices, monitor and log access requests and sessions via the Fyde Enterprise management console. Fyde Enterprise includes features for today’s complex IT environments, enabling security teams to deliver:

Zero Trust on any infrastructure or platform

  • Grant minimal privileged access to authorized apps without exposing the network
  • Work on Mobile or Desktop
  • Deploy on-premises or in hybrid or public cloud
  • Continuously verify users and devices

Global Security and Access Policies

  • Create robust access policies and gain visibility into who has access, to what and from where
  • Assign role-based and attribute-based policies

Upgraded performance and privacy

  • Eliminate latency via local inspection
  • Offer self-service remediation
  • Reduce IT Costs
  • Secure the data plane: Fyde does not have visibility into data.
  • Protect employee privacy. No personal data is shared with the company.

Pricing and availability

Fyde Enterprise is available today. Fyde is sold as an annual subscription with pricing starting at $10 per user per month. Enterprise bundles are available. To try Fyde today, visit Fyde.com/sign-up

About Fyde

Fyde is the new standard for Zero Trust secure access. An increasingly decentralized world is driving digital transformation and challenging the status quo. Fyde helps organizations mitigate risks while adapting to the new nature of work and IT, powering their journey to the Zero Trust Architecture. Our innovative approach is driven by patented technology that enables secure, reliable and fast access to any on-premises, cloud or hybrid app or workload. Fyde eliminates security risks associated with traditional VPN access, while protecting user identities from account takeover attacks. To learn more about Fyde, visit Fyde.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S.
Dawn van Hoegaerden
Fyde
dawn@fyde.com
@dawnvanh

Portugal
Carla Silva
Fyde
carla@fyde.com

Fyde, Inc.
425 Sherman Ave.
Suite 220
Palo Alto CA 94306
USA
+1 650 275 2835

Fyde Portugal
Rua D. João IV, 429
4000-303 Porto
Portugal
+351 919 289 288

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release

Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation

Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 12:00:00 EEST | Press release

Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key Takeaways What Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-source project — now adopted by 1,500+ data teams, with 1.1M + monthly downloads, and a ~4,000-member community. In 2024, it launched Elementary Cloud which added enterprise-grade capabilities on t

Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 11:00:00 EEST | Press release

Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye